Abstract
COX-2 selective inhibitors and conventional NSAIDs have been implicated in negative effects on BP control in treated hypertensive patients. During clinical development of the first COX-2 selective inhibitors, rofecoxib and celecoxib, rates of destabilization of BP control were significantly higher on rofecoxib (14–17%) vs celecoxib (7–11%). Less is known about valdecoxib, a COX-2 selective inhibitor that has been studied in doses of 10–80 mg/d and is approved to treat chronic arthritis at 10 mg/d and menstrual pain at 20–40 mg/d. The incidence of clinically significant hypertension (SBP ≥140 mmHg plus a > 20 mmHg SBP increase) was assessed in 1896 treated hypertensive patients in valdecoxib clinical trials (6–26 weeks duration, median exposure 12 weeks). Proportions of patients developing hypertension were compared for valdecoxib, placebo and the NSAIDs naproxen, diclofenac, and ibuprofen (at maximal osteoarthritis doses). The SBP effects of each dose of valdecoxib (10, 20, 40, 80 mg/d) were also assessed. The incidence of clinically significant hypertension was similar for valdecoxib, NSAIDs, and placebo (Table). P > .20 vs valdecoxib; P > .20 vs naproxen; P = .195 vs naproxen. P > .20 vs valdecoxib; P > .20 vs naproxen; P = .195 vs naproxen. At 40 and 80 mg, valdecoxib showed increased proportions of patients with hypertension vs naproxen, but the difference was not significant. These findings suggest that BP destabilization on valdecoxib is similar to conventional NSAIDs. Further, valdecoxib has BP effects resembling celecoxib rather than rofecoxib in the treated hypertensive patient.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.